The breadth of protection mediated by anti-N2 neuraminidase antibody responses relies on cross-reactive and not cross-inhibiting antibodies
Laura AmelinckiD, Anouk SmetiD, Tine YsenbaertiD, Koen SedeyniD, William Warren, Raúl C. Gomila, Thorsten U. VogeliD, Xavier SaelensiD, João Paulo Portela CataniiD
Abstract
Neuraminidase (NA) inhibition (NAI) titers have been identified as an independent correlation of protection against influenza. Few studies, however, have investigated the breadth of NA-based immune protection. Previously, we have reported that N2 NAs derived from human H3N2 viruses that circulated between 2009 and 2017 can be subdivided into four antigenic groups. Here, we immunized mice with recombinant soluble tetrameric NA from H3N2 strains representing those four antigenic groups or passively transferred N2 NA immune serum into naive mice to evaluate the breadth of protection against a heterologous HxN2 influenza virus challenge. We show that the breadth of protection goes beyond the breadth of NAI but still requires the presence of cross-reactive antibodies. Interestingly, in the absence of cross-reactive antibodies, the immunization of DBA/2J mice with heterologous NA was associated with an early onset of disease upon challenge with the reassortant HxNind11 or H2N2 A/Singapore/1/1957.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans
P. Rijal, B. B. Wang, … K.-Y. A. Huang·bioRxiv·Jun 26, 2019
- Neuraminidase-Based Cross-Protective Immunity against H5N1 Influenza Viruses in Humans
Iván Sanz-Muñoz, Carlos J. Ciria-Gil, … Aitor Nogales·bioRxiv·Jun 12, 2026
- Fc-dependent protective efficacy of non-inhibitory antibodies targeting influenza A virus neuraminidase is limited by epitope availability
Mirte N. Pascha, Marlies Ballegeer, … Cornelis A. M. de Haan·bioRxiv·Sep 3, 2024
- Modernizing the original influenza vaccine to enhance protective antibody responses against neuraminidase antigens
M. Rakic-Martinez, J. Gao, … R. Daniels·bioRxiv·Feb 20, 2023
- The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017
J. P. Catani, A. Smet, … T. U. Vogel·eLifePeer-reviewed·May 28, 2024
- Structure and function of a cross-neutralizing influenza neuraminidase antibody that accommodates recent N2 NA Asn245 glycosylation
Xueyong Zhu, Ahmed Magdy Khalil, … James J. Kobie·Communications BiologyPeer-reviewed·Oct 6, 2025